Page last updated: 2024-12-07

2-mercaptomethyl-3-guanidinoethylthiopropionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-mercaptomethyl-3-guanidinoethylthiopropionic acid: RN given refers to (+-)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123726
SCHEMBL ID2231293
SCHEMBL ID20787654
MeSH IDM0094621

Synonyms (28)

Synonym
2-mmgetpa
2-mercaptomethyl-3-guanidinoethylthiopropionic acid
propanoic acid, 3-((2-((aminoiminomethyl)amino)ethyl)thio)-2-(mercaptomethyl)-, (+-)-
plummer's carboxypeptidase inhibitor
mergepta
mergetpa
2-[2-(diaminomethylideneamino)ethylsulfanylmethyl]-3-sulfanylpropanoic acid
77102-28-4
unii-x8eod1x17q
2-mercaptomethyl-3-guanidinoethylthiopropanoic acid
x8eod1x17q ,
SCHEMBL2231293
compound 3 [pmid: 14640538]
gtpl8675
dl-2-mercaptomethyl-3-guanidinoethyl-thiopropanoic acid
mgta
2-(mercaptomethyl)-3-(guanidinoethylthio)propionic acid, (+/-)-
2-(mercaptomethyl)-3-(guanidinoethylthio)propionic acid
dl-2-(mercaptomethyl)-3-(guanidinoethyl)thiopropanoic acid
propanoic acid, 3-((2-((aminoiminomethyl)amino)ethyl)thio)-2-(mercaptomethyl)-
Q27076625
SCHEMBL20787654
2-{[(2-carbamimidamidoethyl)sulfanyl]methyl}-3-sulfanylpropanoic acid
DTXSID10998363
pmid14640538c3
3-[(2-carbamimidamidoethyl)sulfanyl]-2-(sulfanylmethyl)propanoic acid
HY-W704574
CS-0812597

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" With the octapeptide in vivo dose-response studies were performed."( In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.
Baum, HP; Bitter-Suermann, D; Böttger, EC; Hadding, U; Hoffmann, T; Messner, M, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1345390Human Carboxypeptidase N, polypeptide 1 (M14: Carboxypeptidase A)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID1345328Human Carboxypeptidase M (M14: Carboxypeptidase A)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID1345336Human Carboxypeptidase B1 (tissue) (M14: Carboxypeptidase A)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID1345703Human Carboxypeptidase B2 (plasma) (M14: Carboxypeptidase A)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (34.09)18.7374
1990's18 (40.91)18.2507
2000's9 (20.45)29.6817
2010's2 (4.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.43 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (97.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]